Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Sermorelin
Beginner tier: 200 mcg, daily · community consensus
Also known as: Geref, GRF 1-29, GHRH(1-29)NH2
FDA-approved as Geref in 1990, then discontinued by EMD Serono in 2008; FDA found the withdrawal was not for safety or effectiveness reasons. The sermorelin peptide (Geref) is the first 29 amino acids of endogenous growth hormone releasing hormone (GHRH), the biologically active fragment that fully retains pituitary GHRH receptor binding. A 1997 trial gave 19 adults aged 55 to 71 a close sermorelin analog, [Nle27]GHRH(1-29), every night for 16 weeks (Khorram et al.)[1]. Skin thickness rose and IGF-1 climbed early before easing back by week 16; lean mass rose in men only, and sleep quality didn't change. The Geref label reports that a large proportion of patients develop anti-GRF antibodies at least once during treatment, often transiently. In the children studied, the antibodies did not appear to affect growth. The adult trials are small; a 1992 study gave 10 older men GHRH(1-29) twice daily for 14 days (PMID 1379256 (opens in a new tab)). Community consensus still treats it as the most conservative GH secretagogue, the one to start before the CJC-1295 and ipamorelin combo.
What Is Sermorelin?
Twenty-nine amino acids. That's what separates the sermorelin peptide (also known as Geref or GRF 1-29) from the full 44-amino-acid endogenous GHRH molecule, and those 29 amino acids are the only ones that matter for receptor binding. Sermorelin acetate (CAS 86168-78-7) is a synthetic analog of human GHRH(1-29)NH2 that retains complete GHRH receptor affinity on pituitary somatotroph cells.
The mechanism is direct. Sermorelin binds the GHRH receptor, triggering pulsatile GH release that mirrors the body's natural secretion pattern. Unlike exogenous growth hormone injections, this preserves the hypothalamic-pituitary feedback loop. The pituitary decides how much GH to release; sermorelin just gives it a stronger signal to do so. That distinction matters for long-term safety.
Khorram and colleagues gave 19 adults aged 55 to 71 a nightly GHRH analog, [Nle27]GHRH(1-29)-NH2 [1]. Treatment ran 16 weeks after a 4-week placebo run-in. IGF-1 rose within two weeks, then drifted back toward baseline by week 16. Skin thickness rose, and lean mass increased in men only; sleep quality and fat mass didn't change.
The Geref International Study Group [2] treated 110 GH-deficient children with 30 mcg/kg/day for up to a year. Height velocity in the 86 children analyzed rose from 4.1 to 7.2 cm per year at 12 months. A later review [4] notes that data in a few children suggest the effect holds through 36 months. Subcutaneous bioavailability sits at approximately 6% per the Geref product label, which is expected for GHRH analogs and still produces reliable pharmacological GH pulses.
In practice, sermorelin is the "start here" peptide on r/Peptides (roughly 95,000 subscribers). Community dosing runs 200 to 300 mcg nightly, almost always co-injected with ipamorelin for dual-pathway GH release. Sleep improvement within the first two weeks is the most consistently reported early effect across hundreds of threads. Body composition shifts require two to three months of patience. No new large RCTs for anti-aging indications have been published between 2024 and 2026, so the adult off-label evidence base relies on the 1990s clinical data combined with a large, consistent community experience.
Compared to CJC-1295 (No DAC), sermorelin has a measured half-life, 11 to 12 minutes on the Geref label. It also has more clinical data and an FDA approval history. Geref Diagnostic was approved in 1990 (therapeutic Geref in 1997), and both were discontinued in 2008, and FDA withdrew its approvals effective June 18, 2009 (74 FR 23407). CJC-1295 has zero completed human trials for anti-aging indications.
How Sermorelin Works
Sermorelin binds the growth hormone releasing hormone receptor (GHRH-R) on anterior pituitary somatotroph cells. This is the same receptor that endogenous GHRH activates to trigger natural GH secretion. The 1-29 amino acid fragment retains full receptor binding affinity because the N-terminal portion of GHRH contains all the structural elements needed for GHRH-R recognition and activation.
Once GHRH-R activates, it triggers intracellular cyclic AMP signaling in somatotrophs. That cascade opens calcium channels, prompting GH vesicle release into circulation. The resulting GH pulse peaks at approximately 30 to 60 minutes post-injection and clears quickly. The Geref label gives sermorelin a plasma half-life of 11 to 12 minutes after IV or subcutaneous dosing. The short half-life is actually a feature. It produces a discrete pulse rather than sustained tonic GH elevation, preserving the natural pulsatile secretion rhythm.
The downstream chain follows a predictable path. Pulsatile GH stimulates hepatic IGF-1 synthesis, and IGF-1 mediates most of the tissue-level effects: protein synthesis, lipolysis, collagen production, and bone metabolism. Because sermorelin works through the pituitary rather than replacing GH directly, the hypothalamic feedback loop stays intact. Somatostatin still is the natural brake on GH secretion. This self-limiting mechanism is why supraphysiological GH levels are uncommon with sermorelin at standard doses.
The antibody issue is worth understanding mechanistically. Sermorelin is a foreign peptide analog. Repeated daily injection can trigger an adaptive immune response. The Geref label reports that a large proportion of patients develop anti-GRF antibodies at least once during treatment, often transiently. In the children studied, the antibodies did not appear to affect growth. Cycling cuts total antigen exposure, which is why many protocols build in breaks.
Sermorelin Benefits
- Sermorelin benefits center on GH release through your own pituitary, which community users favor as the conservative route. The largest trial was in GH-deficient children; adult studies are small.
- Improved sleep depth and duration within one to two weeks of starting is the most consistently first-reported benefit across hundreds of r/Peptides threads. A placebo-controlled trial in older adults found no change in sleep quality after 16 weeks of a GHRH analog (Khorram et al. 1997)[1].
- Skin thickness rose in men and women aged 55 to 71 after 16 weeks of a nightly GHRH analog. Lean mass rose in men only, and fat mass didn't change (Khorram et al. 1997)[1].
- Height velocity in GH-deficient children rose from 4.1 to 7.2 cm per year after 12 months on 30 mcg/kg/day (Geref International Study Group)[2]. No adverse biochemical or hormonal changes turned up. A later review [4] cites data in a few children suggesting the effect holds through 36 months.
- Preserved pituitary feedback. Unlike exogenous GH, sermorelin works through the GHRH receptor, keeping the somatostatin brake functional and making supraphysiological GH levels unlikely at standard doses.
- Better workout recovery by weeks three to four is widely reported in community threads, with reduced muscle soreness and faster bounce-back between training sessions.
- Skin hydration and texture improvements at months three and beyond, consistent with GH-driven collagen synthesis.
Sermorelin: Science vs Community Consensus
Mechanism well-established: sermorelin is the 1–29 N-terminal fragment of endogenous GHRH, fully retaining GHRH receptor (GHRH-R) binding activity and stimulating pulsatile GH release from the pituitary somatotrophs.
Read the evidence (key study, limitations)
FDA-approved 1990 and 1997 (Geref) for GH deficiency diagnosis and pediatric GH deficiency treatment; discontinued by EMD Serono in 2008; FDA found the withdrawal was not for safety or effectiveness reasons, and both approvals were withdrawn in 2009. In GH-deficient children, nightly dosing raised height velocity in an open-label study [2]. A randomized trial of 60 GH-deficient children compared GH with a GHRH(1-29)-NH2 infusion [5]. GH grew them faster: 14.6 vs about 9.2 cm/yr at 6 months. Khorram et al. 1997 [1] gave 19 adults aged 55 to 71 a nightly [Nle27]GHRH(1-29) analog for 16 weeks. IGF-1 rose early but drifted back toward baseline by week 16; skin thickness rose, lean mass rose in men only, and sleep quality didn't change. The Geref label reports that a large proportion of patients develop anti-GRF antibodies at least once during treatment, often transiently. In the children studied, the antibodies did not appear to affect growth. No new large RCTs published 2024–2026 for anti-aging off-label indications.
Khorram et al. 1997 (PMID 9141536): nightly SC [Nle27]GHRH(1-29)-NH2 for 16 weeks in 19 adults aged 55 to 71. IGF-1 up by week 2, back toward baseline by week 16; skin thickness up, lean mass up in men only, sleep quality unchanged. Geref International Study Group (PMID 8772599): 30 mcg/kg/day SC in 110 GH-deficient children (86 analyzed). Height velocity 4.1 to 7.2 cm/yr at 12 months.
The adult studies are small. Khorram 1997 gave 19 adults aged 55 to 71 an analog for 16 weeks (PMID 9141536). Corpas 1992 gave 10 older men GHRH(1-29) for 14 days (PMID 1379256). The largest trial was in 110 GH-deficient children (PMID 8772599). No large modern RCT has tested adult anti-aging or body composition use. Off-label dosing (200–500 mcg adult) is community-derived, not established by an RCT. Antibody formation data from the original Geref label (pre-2008): long-term antibody impact in current compounded formulations not re-studied. SC bioavailability ~6% (expected for GHRH analogs).
Widely regarded as the most conservative, beginner-appropriate GH secretagogue.
Read the reports (what users report 5, common issues 5)
"Start here before CJC/Ipa" is the dominant consensus. Primary uses: sleep optimization, anti-aging, modest body recomposition. Nearly always stacked with ipamorelin to pair a GHRH signal with a GHRP pulse.
- Improved sleep depth and duration: most consistent first-reported benefit (weeks 1–2)
- Better workout recovery and reduced soreness by weeks 3–4
- Gradual fat loss and improved muscle tone over months 2–3
- Improved skin hydration and quality at months 3+
- Well-tolerated: low side-effect burden relative to synthetic GH
- Slow onset: visible body composition changes require 2–3 months; common expectation mismatch
- Efficacy plateau or loss after 4–6 months in continuous non-cycled users (antibody formation)
- Strict pre-injection fasting required (2+ hours): compliance is the most common failure point
- Facial flushing and mild headache common in first 1–3 weeks post-injection
- Results modest vs. CJC-1295/ipamorelin stack: some users switch after first cycle
Science and community agree on GHRH-R mechanism, pulsatile GH release, and SC nightly dosing. Community doses (200–500 mcg nightly) sit below the doses older-adult studies used (10 mcg/kg nightly, PMID 9141536; 1 mg twice daily, PMID 1379256). Bedtime administration, empty stomach requirement, and 5-day cycling are all mechanistically grounded in published pharmacology. Primary divergence: community almost always stacks sermorelin with ipamorelin while clinical trials tested sermorelin monotherapy. Antibody formation concern is present in both clinical data and community experience.
Sermorelin Dosage Guide
With a 5 mg vial and 2 mL bacteriostatic water, you get 2,500 mcg/mL. At that concentration: 200 mcg is 8 units on a U-100 insulin syringe, 300 mcg is 12 units, and 500 mcg is 20 units.
The fasting window is where most beginners fail. You need at least two hours with no food before the injection. Insulin triggers somatostatin release from the hypothalamus, which directly opposes GH secretion. Eating within that window doesn't just reduce the effect; it negates it.
Bedtime dosing is the priority. Sermorelin amplifies the natural nocturnal GH pulse during slow-wave sleep. Inject 30 to 60 minutes before sleep for best results.
Store reconstituted vials at 2 to 8 degrees Celsius. Discard anything cloudy or with visible particles. Lyophilized powder is more stable but still belongs in the fridge.
If you see no sleep improvement after two weeks with correct timing, check your reconstitution math first. Then get an IGF-1 draw at week six. If IGF-1 isn't moving, suspect the product quality before blaming the peptide.
Most users stack sermorelin with ipamorelin. The two hit different receptor pathways (GHRH-R and GHS-R1a), and community reports describe a combined GH pulse larger than either alone.
The Geref label reports that a large proportion of patients develop anti-GRF antibodies at least once during treatment, often transiently. In the children studied, the antibodies did not appear to affect growth. Their effect on results in adults is not studied. The antibody response is driven by repeated antigen exposure. Cycling (5-days-on/2-days-off and periodic 4-week breaks) reduces total antigen exposure, mitigates immune sensitization, and helps maintain long-term pituitary responsiveness.
- Declining sleep quality improvement despite consistent dosing (months 4–6)
- IGF-1 levels plateauing or declining after initial elevation on the same dose
- Loss of recovery and energy benefits previously present on the same protocol
- Reduced or absent facial flushing post-injection (may indicate diminished GH pulse response)
Or use the universal Peptide Calculator for any peptide.
Sermorelin Protocols by Goal
Expected: Improved sleep quality (weeks 1–2), better recovery (weeks 3–4), modest lean mass gain and fat loss (months 2–3), improved skin quality (months 3+)
Monitor: IGF-1 baseline, week 6, month 3, month 6. Fasting glucose baseline and every 3 months. Thyroid panel at baseline (hypothyroidism blunts GH response).
Who Uses Sermorelin?

Neuroscientist & Stanford Professor
I stopped taking it because REM depletion was something I didn't want.
How to Use Sermorelin
- 1Reconstitute the vial
Pull 2 mL of bacteriostatic water into a 29 to 31 gauge insulin syringe. For a 5 mg vial, this gives 2,500 mcg per mL. Let the water run slowly down the inside wall of the vial. Never spray directly onto the lyophilized powder. Swirl gently until fully dissolved.
- 2Calculate your syringe units
At 2,500 mcg/mL (5 mg vial + 2 mL BAC water): 200 mcg = 8 units, 300 mcg = 12 units, 500 mcg = 20 units on a U-100 insulin syringe.
- 3Confirm fasting
Minimum two hours since your last meal. No food for 30 minutes after injection, either.
- 4Clean the injection site with an alcohol swab
Abdomen (periumbilical area, avoiding the navel) or lateral thigh. Rotate sides with each injection.
- 5Pinch the skin at the injection site
Insert the needle at a 45-degree angle. Inject slowly and hold for five seconds before withdrawing. Use a 27 to 31 gauge, 5/16 inch or 3/8 inch needle.
- 6Step 6
If stacking with ipamorelin, draw sermorelin first, then ipamorelin into the same syringe. Co-inject at the same site and time. For a typical beginner stack: 8 units sermorelin (200 mcg from a 5 mg/2 mL vial) plus 20 units ipamorelin (200 mcg from a 2 mg/2 mL vial).
- 7Inject 30 to 60 minutes before sleep
Store the reconstituted vial in the refrigerator immediately after use.
Cycling: 5 days on, 2 days off (for example, Monday through Friday). Take a full four-week break after each three-to-six-month cycle to prevent antibody formation.
Alternative Routes
Reference route; all published dosing data based on SC administration
SC bioavailability ~6% (Geref label). Despite low absolute bioavailability, SC reliably produces pharmacological GH pulses. Inject into abdomen (periumbilical) or lateral thigh fat, rotating sites. 27–31G 5/16" or 3/8" insulin needle standard.
Bioavailability unknown: no PK study comparing sublingual vs. SC sermorelin published as of April 2026. Tablets marketed at $79–$139/month; dose equivalence to SC injection unestablished.
Sublingual sermorelin tablets are now available through some telehealth platforms. Sermorelin is a 29-amino-acid peptide: sublingual absorption of intact peptides is generally low due to protease activity and mucosal impermeability. Patients should understand this is an unvalidated route with no comparative efficacy data vs. the clinically established SC route.
Intranasal bioavailability for GHRH analogs estimated ~20% of SC in limited studies; sermorelin-specific intranasal PK data not published
Not a standard clinical or commercial route for sermorelin. Some compounding pharmacies have prepared intranasal formulations but this is not supported by published efficacy data for sermorelin specifically.
Sermorelin Stacking Protocols
Works With
The most common community pairing. Ipamorelin acts on GHS-R1a, a different receptor from sermorelin's GHRH-R, and community reports describe a larger GH pulse from the pair than from either alone. In swine, ipamorelin released GH without raising ACTH or cortisol (PMID 9849822).
200 mcg sermorelin + 200 mcg ipamorelin co-injected SC, 30–60 min before sleep
Added for systemic recovery, gut health, and injury healing while sermorelin handles GH optimization. No direct pharmacokinetic interaction. Injected separately at a different site and timing.
BPC-157 250–500 mcg SC separate injection, separate site; timing flexible
Added to sermorelin protocols for enhanced tissue repair and anti-inflammatory effects, particularly in athletes. GH optimization (sermorelin) + systemic healing (TB-500) is a popular body recomposition stack.
TB-500 2–5 mg SC 1–2× per week; separate injection from sermorelin
Avoid
Both are GHRH-R agonists: concurrent use is redundant and provides receptor competition without additive benefit. Tesamorelin is significantly more potent; combining does not amplify effect. Choose one GHRH analog per cycle.
Do not combineCJC-1295 DAC produces a prolonged continuous GHRH signal (t½ ~7 days) that is mechanistically incompatible with sermorelin's pulsatile GHRH approach. The DAC formulation blunts GH pulsatility that sermorelin is designed to optimize. Concurrent use is counterproductive and redundant.
Do not combineChronic glucocorticoid use blunts pituitary GH secretion and reduces the IGF-1 response to sermorelin. Documented in the Geref prescribing information as a drug interaction. Short-course steroids have minimal impact; chronic use substantially reduces sermorelin efficacy.
Somatostatin analogs directly suppress GH release from pituitary somatotrophs: pharmacologically opposing sermorelin's mechanism. Concurrent use eliminates sermorelin efficacy.
Do not combineHow much does Sermorelin cost?
Typical price
$5.95 to $8.00 per mg
Middle half of 63 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
Sermorelin Side Effects
Antibody formation is the main long-term question with sermorelin. The Geref label reports that a large proportion of patients develop anti-GRF antibodies at least once during treatment, often transiently. In the children studied, the antibodies did not appear to affect growth. The label also links them to no specific adverse reaction profile. Users who skip cycling and run sermorelin continuously for six-plus months commonly report complete loss of effect. Community protocols respond by cutting injection frequency (5 days on, 2 days off) and taking periodic four-week breaks.
Facial flushing is the most common acute side effect. It typically occurs 20 to 30 minutes after injection and results from the vasodilatory response to acute GH release. Community reports and clinical data both describe this as transient, resolving within an hour, and most prominent during the first one to three weeks of use. It does not require dose adjustment unless severe.
Headache and dizziness post-injection are reported at moderate frequency. Like flushing, these relate to the acute GH pulse. They tend to resolve by weeks three to four without intervention. If persistent, reducing the dose by 50 mcg usually handles it.
Injection-site reactions (redness, minor irritation, occasional nodules) are expected with any subcutaneous peptide. Consistent site rotation and allowing refrigerated peptide to reach room temperature before injecting both reduce incidence. Nodules persisting beyond one week warrant switching to a different anatomical region.
GH-mediated insulin resistance is a theoretical concern with any GH-raising therapy. Sermorelin produces physiological (not supraphysiological) GH pulses, so the risk is lower than with exogenous GH. Still, fasting glucose monitoring every three months is appropriate, especially for anyone over 40 or carrying metabolic risk factors. A fasting glucose above 126 mg/dL means stopping.
GH promotes cell proliferation. Active cancer, a history of malignancy, or active pituitary tumors are absolute contraindications. If IGF-1 surpasses the age-adjusted upper normal range, the dose should be reduced or the protocol discontinued.
Untreated hypothyroidism impairs GH response to sermorelin (Geref contraindications). GH also accelerates T4-to-T3 conversion, so thyroid function may shift during use. Baseline thyroid panel is recommended.
Pregnancy and breastfeeding are contraindicated. Effects on fetal development have not been established.
When to see a doctor: persistent edema, fasting glucose above 126 mg/dL, joint pain unresponsive to dose reduction, symptoms of intracranial hypertension, or any sign of glucose intolerance.
Common Issues & Solutions
No sleep improvement after 2 weeks → verify timing (30–60 min pre-sleep, ≥2 hours fasted); confirm reconstitution math (5 mg + 2 mL BAC water = 2,500 mcg/mL; 200 mcg = 8 units); confirm vial is refrigerated at 2–8°C and solution is clear.
Efficacy plateau or loss after 4–6 months → antibody formation is one suspect, though on the Geref label antibodies were often transient and did not appear to affect growth in the children studied; implement strict 5-on/2-off cycling if not already doing so; schedule a 4-week complete break; efficacy typically returns post-break.
IGF-1 not rising after 6–8 weeks at 200 mcg → dose may be subtherapeutic; titrate to 300 mcg; rule out concurrent hypothyroidism (check TSH/T3/T4), chronic glucocorticoid use, or injection technique error (IM vs. SC).
Facial flushing, headache, or dizziness post-injection → benign vasodilatory response to GH release; typically resolves by weeks 3–4 without dose change; if severe or persistent, reduce dose by 50 mcg; does not require discontinuation.
Injection site nodules or persistent irritation → rotate sites consistently (alternating abdominal sides, lateral thighs); allow refrigerated peptide to reach room temperature before injecting; confirm SC technique (not IM depth); switch anatomical region if nodules persist >1 week.
Ask AI about this page
Ask AI for a second opinion on Sermorelin dosing and side effects
Contraindications
- Active cancer or history of malignancy: GH promotes cell proliferation and tumor growth
- Pregnancy or breastfeeding: effects on fetal development have not been established
- Active pituitary tumors or intracranial neoplasms
- Known hypersensitivity to sermorelin acetate or any excipients
- Untreated hypothyroidism: may impair GH response to sermorelin
Drug Interactions
- Glucocorticoids (prednisone, dexamethasone): chronic use may blunt GH response and reduce sermorelin efficacy
- Insulin and oral hypoglycemics: GH release antagonizes insulin action; glucose monitoring required
- Somatostatin analogs (octreotide, lanreotide): directly inhibit GH release, counteracting sermorelin effects
- Cyclooxygenase inhibitors (aspirin, indomethacin): may alter GH response to sermorelin
- Thyroid hormones: GH can accelerate T4-to-T3 conversion; monitor thyroid function during concurrent use
- Muscarinic antagonists (atropine): may modify the GH-releasing response
- Chronic glucocorticoid use blunts pituitary GH secretion and reduces the IGF-1 response to sermorelin. Documented in the Geref prescribing information as a drug interaction. Short-course steroids have minimal impact; chronic use substantially reduces sermorelin efficacy.
Product Quality
Sermorelin was the active ingredient of an FDA-approved drug (Geref), and US clinics prescribe it compounded rather than as a research chemical. As a compounded (not FDA-manufactured) product, GMP compliance, sterility, and potency are pharmacy-dependent and unverified by FDA. Grey-market research chemical vials exist and carry substantially higher contamination and misdosing risk.
- Source exclusively from licensed 503A compounding pharmacies with a valid clinician prescription
- A certificate of analysis (COA) or potency/sterility report documents a compounded batch; licensed 503A compounders can provide one
- Verify reconstitution math independently: 5 mg vial + 2 mL BAC water = 2,500 mcg/mL; 200 mcg = 8 units on a U-100 insulin syringe
- Refrigerate reconstituted vials at 2–8°C; discard if solution is cloudy, discolored, or contains visible particulates
- Research-chemical products without an independent third-party COA carry real risk: underdosing and contamination are documented in the grey market
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | Baseline; week 6; month 3; month 6; after each cycling restart | Age- and sex-adjusted mid-normal range (typically 150–300 ng/mL in adults 30–60; labs provide age-specific reference ranges) |
| Fasting glucose | Baseline; every 3 months during use | Fasting glucose <100 mg/dL normal; 100–125 prediabetic (consider dose reduction); ≥126 mg/dL (stop) |
| Thyroid panel (TSH, Free T3, Free T4) | Baseline; repeat if symptoms emerge or if IGF-1 fails to rise | TSH 0.5–4.5 mIU/L; Free T4 and Free T3 within laboratory reference range |
| HbA1c | Baseline; every 6 months (every 3 months if >45 years, overweight, or family history of T2DM) | <5.7% normal; 5.7–6.4% prediabetes (reduce dose, increase monitoring); ≥6.5% (stop) |
Primary biomarker for GH axis activity. Tracks cumulative 24-hour GH output. Supranormal IGF-1 indicates dose is too high.
GH induces insulin resistance. Sermorelin produces physiological (not supraphysiological) GH pulses, but fasting glucose monitoring is appropriate for any GH-elevating therapy, especially in individuals over 40 or with metabolic risk factors.
Untreated hypothyroidism significantly impairs GH response to sermorelin (Geref contraindications). GH can also accelerate T4→T3 conversion: thyroid function may shift with prolonged GH elevation.
Long-term glycemic impact assessment. Less acute than fasting glucose but reflects 3-month average; appropriate for longer cycles.
Sermorelin Before and After
Improved sleep depth and quality often noticed first. Mild facial flushing may occur around injection time. GH pulses begin to normalize.
Recovery between workouts improves. Energy and mood stabilize. Skin hydration begins to improve as IGF-1 levels rise.
Body composition shifts become measurable: modest fat loss, improved muscle tone. Hair and nail growth may accelerate. Joint comfort improves.
Users report peak benefits for body composition, sleep and recovery. In the 1997 Khorram trial, IGF-1 drifted back toward baseline by week 16 while skin thickness rose.
Benefits are sustained with continued use. Periodic IGF-1 monitoring recommended. Some practitioners cycle 5 days on, 2 days off to maintain pituitary sensitivity.
What to Expect
Weeks 1 to 2: GH pulse normalization begins within days of the first injection. Pituitary somatotrophs need roughly one to two weeks of repeated GHRH-R stimulation to upregulate secretory capacity. Plasma IGF-1 starts climbing. Sleep is the first thing most users notice, usually within the first week. Deeper onset, longer slow-wave phases, vivid dreams. Mild facial flushing 20 to 30 minutes post-injection is common and expected. Light headache and brief dizziness may accompany the flush. Both resolve as the body adjusts.
Weeks 3 to 4: IGF-1 becomes measurably raised above baseline. Recovery between workouts picks up. Reduced muscle soreness and more stable daytime energy are the consistent community reports at this stage. Skin hydration starts improving as GH-driven collagen synthesis kicks in. Facial flushing typically fades by now. Injection-site reactions still happen if sites aren't rotated consistently.
Months 2 to 3: Body composition shifts become measurable. In the 1997 Khorram trial [1], lean mass rose in men only after 16 weeks of a GHRH analog, and fat mass didn't change. Community reports go further, with modest fat loss around the midsection, improved muscle definition, better skin texture. Nail and hair growth may accelerate. Joint comfort tends to improve.
Months 4 to 6: Community reports put the peak window for body composition, sleep and recovery here. In the 1997 analog trial, IGF-1 rose early but drifted back toward baseline by week 16 [1]. Skin thickness rose in both sexes in that trial. This is also where continuous (uncycled) users start noticing antibody-driven efficacy loss. If benefits suddenly plateau around month five or six and you haven't been cycling, antibody formation is the most likely explanation.
Month 6 and beyond (with cycling): Appropriate cycling (5 days on, 2 days off, plus periodic four-week breaks) keeps pituitary sensitivity intact and slows antibody formation. No published RCTs extend past six months for anti-aging sermorelin use; long-term safety data is extrapolated from the pediatric GH deficiency literature. Community users who cycle report sustained benefits over multiple cycles spanning a year or more. Continuous non-cycled users report progressive non-response, sometimes reaching full loss of efficacy within 6 to 12 months. IGF-1 monitoring every three months is the standard approach for long-term protocols.
Detailed Timeline: Science vs Community
GH pulses begin normalizing within days. Pituitary somatotrophs require ~1–2 weeks of GHRH-R stimulation to upregulate GH secretory capacity. Plasma IGF-1 begins to rise.
Improved sleep depth and ease of falling asleep is the most consistently reported first effect. Vivid dreams common. Mild facial flushing 20–30 min post-injection.
IGF-1 measurably elevated above baseline. GH-driven protein synthesis and lipolysis beginning. Controlled sleep data is thin. The 1997 analog trial found self-rated sleep quality unchanged after 16 weeks (PMID 9141536).
Reduced muscle soreness after workouts. More stable daytime energy and mood improvements reported. Facial flushing side effect typically resolving by this point.
Khorram et al. 1997 (PMID 9141536) gave adults aged 55 to 71 a nightly GHRH analog for 16 weeks. Lean mass rose in men only, fat mass didn't change, and skin thickness rose in both sexes. Skin collagen synthesis increases with sustained GH elevation.
Modest but noticeable fat loss around midsection. Improved muscle definition. Skin hydration and texture improving. Nail and hair growth may accelerate.
In the 1997 analog trial (PMID 9141536), IGF-1 rose early but was back toward baseline by week 16. Skin thickness rose in both sexes and lean mass in men only. Sleep quality and bone mineral density did not change over the 16 weeks.
Most users report this as peak benefit period. Lean mass and fat loss most noticeable. Some users on continuous (uncycled) dosing begin noticing antibody-driven efficacy plateau around month 5–6.
Appropriate cycling (5-on/2-off; periodic 4-week breaks) mitigates antibody formation and maintains pituitary sensitivity. No published RCTs beyond 6 months for anti-aging use; long-term data extrapolated from GH deficiency literature.
Experienced cycled users report sustained benefits with periodic breaks. Continuous non-cycled users report progressive efficacy loss over 6–12 months, eventually reaching non-response.
Pharmacokinetics
Source: Geref label, Clinical Pharmacology (as reproduced by RxList): t½ 11-12 min after IV or SC dosing. Soule et al. 1994 (PMID 7962295): 4.3 min disappearance half-time during IV infusion in 10 men
Pharmacokinetics: Active Dose Over Time
t½ = 11-12 min (IV or SC, Geref label)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Sermorelin Legal?
FDA approved sermorelin acetate as Geref in 1990 (NDA 019863), a diagnostic for pituitary GH secretion. A second Geref approval in 1997 (NDA 020443) covered idiopathic GH deficiency in children with growth failure. Geref was discontinued by EMD Serono in 2008; FDA found the withdrawal was not for safety or effectiveness reasons (78 FR 14095). FDA withdrew both approvals effective June 18, 2009 (74 FR 23407), so no FDA-approved sermorelin product exists in the US today.
Sermorelin is not on the 503A bulks list (21 CFR 216.23) or on FDA's list of drugs withdrawn for safety or effectiveness reasons (21 CFR 216.24). FDA's 503B list (updated March 21, 2025) places sermorelin acetate in Category 1, under evaluation, and marks it as a component of an FDA-approved drug. US clinics prescribe compounded sermorelin; no compounded product has FDA approval. Some telehealth services offer sublingual tablets, and no published pharmacokinetic study compares sublingual to subcutaneous dosing.
Athletes should know that sermorelin falls under the WADA 2026 Prohibited List as a Growth Hormone Releasing Factor (S2.2.4). It is detectable and any athlete subject to anti-doping testing should not use it.
This content is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
Who Should Consider Sermorelin
- Adults over 30 experiencing age-related GH decline (somatopause)
- Patients undergoing GH deficiency diagnostic testing
- Individuals seeking a conservative first GH secretagogue (community consensus)
- Adults with poor sleep quality seeking improved deep sleep phases
- Clinicians preferring a peptide with an FDA approval history (Geref, approved 1990, discontinued 2008, approvals withdrawn 2009)
Related Peptides
What Changed for Sermorelin
- Correction
Corrected Oct 17, 2026: the Oct 16 sermorelin entry called all its human data small; one cited trial treated 110 GH-deficient children, per Thorner 1996.
What this does not mean: The evidence rating stays moderate. The adult studies are small: 19 older adults in 1997 and 10 older men for 14 days in 1992. The 1996 trial treated 110 GH-deficient children for up to a year.
Source: Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96. PMID 8772599 (opens in a new tab) · Archived snapshot (opens in a new tab)
- EvidenceCorrected Oct 17, 2026
Corrected Oct 16, 2026: sermorelin's scientific evidence is now rated moderate, not strong, after a re-read of its cited human trials, per PubMed.
Before: strong After: moderate
What this does not mean: Doses, safety grade and FDA history did not change. The cited human data is small: 19 older adults on a GHRH analog in 1997, 10 older men for 14 days in 1992, and GH-deficient children.
Source: Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9. PMID 9141536 (opens in a new tab) · Archived snapshot (opens in a new tab)
- Regulatory
Corrected Oct 10, 2026: sermorelin's US status now records that FDA withdrew both Geref approvals effective Jun 18, 2009, per Federal Register E9-11628.
Before: No sourced US status record After: Not approved in the US. Geref NDA 019863 (Dec 28, 1990) and NDA 020443 (Sep 26, 1997) were discontinued in 2008; FDA withdrew both approvals June 18, 2009 (74 FR 23407), not for safety or effectiveness (78 FR 14095)
What this does not mean: FDA found in 2013 that Geref was not withdrawn from sale for safety or effectiveness reasons (78 FR 14095). Compounded sermorelin is not an FDA-approved product.
Source: Federal Register E9-11628 (74 FR 23407, May 19, 2009): Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications, including NDA 19-863 Geref Diagnostic and NDA 20-443 Geref; effective June 18, 2009 (opens in a new tab) · Saved copy
- Safety
Corrected Oct 10, 2026: sermorelin side effects drop an unsourced 70% antibody rate; on daily GHRH(1-29), antibodies seemed not to hinder growth, per PubMed.
Before: About 70% of continuous users develop neutralizing antibodies by 18 months, credited to the Geref label After: Antibodies form in many patients, often transiently; in 16 prepubertal GH-deficient children on daily GHRH(1-29), they seemed not to interfere with growth (PMID 7735367)
What this does not mean: Antibodies still form in many patients on the Geref label. Users who run sermorelin without breaks still report losing its effect.
Source: J Pediatr Endocrinol 1994, Long-term therapy with a single daily subcutaneous dose of GHRH (1-29) in prepubertal GH deficient children (PMID 7735367) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Regulatory
Corrected Oct 10, 2026: sermorelin's research stage is now discontinued, after FDA withdrew both Geref approvals effective Jun 18, 2009, per Federal Register.
Before: Approved After: Discontinued
What this does not mean: FDA found in 2013 that Geref was not withdrawn from sale for safety or effectiveness reasons (78 FR 14095). The trial data on this page are unchanged.
Source: Federal Register E9-11628 (74 FR 23407, May 19, 2009): Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications, including NDA 19-863 Geref Diagnostic and NDA 20-443 Geref; effective June 18, 2009 (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 7, 202610 Citations
References
- [1]Endocrine and Metabolic Effects of Long-Term Administration of [Nle27]GHRH-(1-29)-NH2 in Age-Advanced Men and Women (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Once Daily Subcutaneous GHRH Therapy Accelerates Growth in GH-Deficient Children During the First Year of Therapy (Geref International Study Group) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency? (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency (Chen et al., Acta Paediatr Suppl 1993) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Geref, Drugs@FDA application record NDA 020443 (approval withdrawn 2009) (opens in a new tab)FDA Label
- Geref (sermorelin acetate) labeling as reproduced in the RxList monograph (secondary source) (opens in a new tab)Review
- Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men (Corpas et al., J Clin Endocrinol Metab 1992) (opens in a new tab)PubMed 1379256PubMed
- Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men (Soule et al., J Clin Endocrinol Metab 1994) (opens in a new tab)PubMed 7962295PubMed
- Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol 1998) (opens in a new tab)PubMed 9849822PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Sermorelin?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
328 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.